New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2014
05:35 EDTJAZZ, GENTJazz announces minimum tender condition exceeded during offering for Gentium
Jazz Pharmaceuticals (JAZZ) announced that the initial offering period in the tender offer made by a subsidiary of Jazz Pharmaceuticals to purchase all outstanding ordinary shares and American Depositary Shares of Gentium S.p.A. (GENT) for $57.00 per share and per ADS in cash expired on the evening of January 22. Jazz Pharmaceuticals today also announced that its subsidiary has commenced a subsequent offering period to acquire the remaining ordinary shares and ADSs of Gentium.
News For JAZZ;GENT From The Last 14 Days
Check below for free stories on JAZZ;GENT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
11:51 EDTJAZZOECD looks to close tax loopholes with new proposals
Subscribe for More Information
September 8, 2014
08:17 EDTJAZZJazz Pharmaceuticals executing on all cylinders, says Stifel
Following management meetings, Stifel reiterates its Buy rating and $195 price target on Jazz Pharmaceuticals given growth opportunities and sustainability of its current portfolio. The firm agrees with the Xyrem franchise expansion strategies through new patient capture near-term, and longer-term, the addition of complementary wakefulness products.
07:21 EDTJAZZJazz looks more attractive for Allergan than Salix, says Wells Fargo
Subscribe for More Information
September 5, 2014
11:40 EDTJAZZJazz Pharmaceuticals calls active on renewed takeover speculation
Subscribe for More Information
11:00 EDTJAZZRumor: Jazz Pharmaceuticals strength attributed to renewed takeover speculation
Subscribe for More Information
September 3, 2014
07:47 EDTJAZZJazz Pharmaceuticals management to meet with Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use